Related Experiment Videos
A study on direct antitumor activity of bropirimine (oral interferon inducer) for renal cell carcinoma
Abstract:
Aryl pyrimidinones, including bropirimine, exert anti-tumor activity through the induction of interferon (IFN)-alpha. Herein, the direct anti-tumor effect of bropirimine on 17 renal cell carcinoma (RCC) surgically obtained was examined using an organ culture system closely resembling the in vivo state, and also using the heterotransplanted nude mouse system. The findings obtained using the organ culture system showed that bropirimine inhibited 3H-thymidine uptake significantly in 15 of the 17 RCC (88.2%) compared with the control. Furthermore, the 3H-thymidine uptake was dose-dependently inhibited in 3 of the 17 tumors (17.6%). The oral administration of bropirimine against RCC heterotransplanted in nude mice (JRC 901: an erythropoietin-producing strain) tended to inhibit tumor growth dose-dependently, but not significantly (mean tumor weight ratio: T/C ratio: over 43%, degeneration degree of tumor: incomplete). However, the production of erythropoietin from the JRC 901 was significantly inhibited. These findings suggest that bropirimine has a direct anti-tumor activity, without the mediation of IFN-alpha induction, against human renal cell carcinoma.
Insights
Bropirimine demonstrates direct anti-tumor effects on renal cell carcinoma (RCC) by inhibiting cell proliferation. This study suggests bropirimine
Area of Science:
- Oncology
- Pharmacology
Background:
- Aryl pyrimidinones, such as bropirimine, are known to induce interferon-alpha (IFN-alpha), contributing to anti-tumor activity.
- The precise mechanism of bropirimine's anti-tumor effect, particularly its direct action, requires further investigation.
Purpose of the Study:
- To investigate the direct anti-tumor effect of bropirimine on human renal cell carcinoma (RCC) ex vivo and in vivo.
- To determine if bropirimine's anti-tumor activity is mediated by interferon-alpha (IFN-alpha) induction.
Main Methods:
- Organ culture system using 17 surgically obtained RCC samples to assess 3H-thymidine uptake inhibition.
- Heterotransplantation of RCC (JRC 901) into nude mice to evaluate tumor growth inhibition and erythropoietin production following bropirimine administration.
Main Results:
- Bropirimine significantly inhibited 3H-thymidine uptake in 88.2% of RCC samples in organ culture.
- Oral administration of bropirimine showed a trend towards dose-dependent tumor growth inhibition in mice but did not reach statistical significance.
- Bropirimine significantly inhibited erythropoietin production in the JRC 901 cell line.
Conclusions:
- Bropirimine exhibits direct anti-tumor activity against human renal cell carcinoma.
- The anti-tumor effect of bropirimine may not be mediated by interferon-alpha (IFN-alpha) induction.
- Bropirimine's ability to inhibit erythropoietin production warrants further study in the context of RCC treatment.